Stockreport

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

Mirati Therapeutics, Inc.  (MRTX) 
Last mirati therapeutics, inc. earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.mirati.com/node/5806